Known targets — ChEMBL curated mechanism
APH1AAPH1BNCSTNPSEN1PSEN2PSENEN
The experimentally established mechanism targets of Nirogacestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 known ✓ | P49768 | 20/20 | 0.99 |
| ▸ | PSEN2 known ✓ | P49810 | 20/20 | 0.99 |
| ▸ | APH1B known ✓ | Q8WW43 | 20/20 | 0.99 |
| ▸ | NCSTN known ✓ | Q92542 | 20/20 | 0.99 |
| ▸ | APH1A known ✓ | Q96BI3 | 20/20 | 0.99 |
| ▸ | PSENEN known ✓ | Q9NZ42 | 20/20 | 0.99 |
| ▸ | GSAP | A4D1B5 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nirogacestat SCHEMBL28508943 | 1.00 | PSEN1 (0.99) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL30074516 | 1.00 | PSEN1 (0.99) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL27231324 | 1.00 | PSEN1 (0.99) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL27231326 | 1.00 | PSEN1 (0.99) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL19183016 | 1.00 | PSEN1 (0.99) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL31142147 | 1.00 | PSEN1 (0.99) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL27214389 | 1.00 | PSEN1 (0.99) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL31142148 | 1.00 | PSEN1 (0.99) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL13184754 | 0.99 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL1796299 | 0.99 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4525828-A1 | TREATMENTS WITH NIROGACESTAT | Springworks Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| US-20250025446-A1 | TREATMENTS WITH NIROGACESTAT | SPRINGWORKS THERAPEUTICS, INC. | 2025-01-23 | — | — | US | claimed |
| US-12138246-B2 | Treatments with nirogacestat | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-11-12 | — | — | US | claimed |
| US-20240245648-A1 | TREATMENTS WITH NIROGACESTAT | SPRINGWORKS THERAPEUTICS, INC. | 2024-07-25 | — | — | US | claimed |
| US-12036207-B2 | Treatments with nirogacestat | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | claimed |
| US-12011434-B2 | Treatments with nirogacestat | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | claimed |
| US-12011435-B2 | Treatments with nirogacestat | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | claimed |
| US-20240180874-A1 | IMPROVED TREATMENT OF OVARIAN CANCER WITH NIROGACESTAT | SPRINGWORKS THERAPEUTICS, INC. | 2024-06-06 | — | — | US | claimed |
| US-20240156784-A1 | TREATMENTS WITH NIROGACESTAT | SPRINGWORKS THERAPEUTICS, INC. | 2024-05-16 | — | — | US | claimed |
| US-20240148695-A1 | TREATMENTS WITH NIROGACESTAT | SPRINGWORKS THERAPEUTICS, INC. | 2024-05-09 | — | — | US | claimed |
| US-20240066007-A1 | TREATMENTS WITH NIROGACESTAT | SPRINGWORKS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | claimed |
| US-20240058305-A1 | TREATMENTS WITH NIROGACESTAT | SPRINGWORKS THERAPEUTICS, INC. | 2024-02-22 | — | — | US | claimed |
| US-20240050410-A1 | TREATMENTS WITH NIROGACESTAT | SPRINGWORKS THERAPEUTICS, INC. | 2024-02-15 | — | — | US | claimed |
| US-20240050411-A1 | TREATMENTS WITH NIROGACESTAT | SPRINGWORKS THERAPEUTICS, INC. | 2024-02-15 | — | — | US | claimed |
| US-11872211-B2 | Treatments with nirogacestat | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | claimed |
| WO-2023225283-A1 | TREATMENTS WITH NIROGACESTAT | SPRINGWORKS THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| US-20230372300-A1 | TREATMENTS WITH NIROGACESTAT | SPRINGWORKS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | claimed |
| US-20230372301-A1 | TREATMENTS WITH NIROGACESTAT | SPRINGWORKS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | claimed |
| US-20230121547-A1 | A COMBINATION THERAPY WITH NIROGACESTAT AND A BCMA-DIRECTED THERAPY AND USES THEREOF | SpringWorks Therapeutics Inc. (US) | 2023-04-20 | — | — | US | claimed |
| EP-4132515-A1 | A COMBINATION THERAPY WITH NIROGACESTAT AND A BCMA-DIRECTED THERAPY AND USES THEREOF | Springworks Therapeutics, Inc. (US) | 2023-02-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12011435-B2 | Treatments with nirogacestat | GBA1, GBA2, RABGGTB | PSEN1 4565/4885PSEN2 3937/4885APH1B 2464/4885 |
| US-20230372300-A1 | TREATMENTS WITH NIROGACESTAT | GBA1, GBA2, RABGGTB | PSEN1 4565/4885PSEN2 3937/4885APH1B 2464/4885 |
| US-20240245648-A1 | TREATMENTS WITH NIROGACESTAT | GBA1, GBA2, RABGGTB | PSEN1 4565/4885PSEN2 3937/4885APH1B 2464/4885 |
| US-20240058305-A1 | TREATMENTS WITH NIROGACESTAT | GBA1, GBA2, RABGGTB | PSEN1 4565/4885PSEN2 3937/4885APH1B 2464/4885 |
| US-20230121547-A1 | A COMBINATION THERAPY WITH NIROGACESTAT AND A BCMA-DIRECTED THERAPY AND USES THEREOF | CD47, CD22, BCL6 | PSEN1 1012/4885PSEN2 1181/4885APH1B 674/4885 |
| US-20230372301-A1 | TREATMENTS WITH NIROGACESTAT | GBA1, GBA2, RABGGTB | PSEN1 4565/4885PSEN2 3937/4885APH1B 2464/4885 |
| US-12011434-B2 | Treatments with nirogacestat | GBA1, GBA2, RABGGTB | PSEN1 4565/4885PSEN2 3937/4885APH1B 2464/4885 |
| US-20240066007-A1 | TREATMENTS WITH NIROGACESTAT | GBA1, GBA2, RABGGTB | PSEN1 4565/4885PSEN2 3937/4885APH1B 2464/4885 |
| US-20240156784-A1 | TREATMENTS WITH NIROGACESTAT | GBA1, GBA2, RABGGTB | PSEN1 4565/4885PSEN2 3937/4885APH1B 2464/4885 |
| US-12138246-B2 | Treatments with nirogacestat | GBA1, GBA2, RABGGTB | PSEN1 4565/4885PSEN2 3937/4885APH1B 2464/4885 |
| US-20240050411-A1 | TREATMENTS WITH NIROGACESTAT | GBA1, GBA2, RABGGTB | PSEN1 4565/4885PSEN2 3937/4885APH1B 2464/4885 |
| US-12036207-B2 | Treatments with nirogacestat | GBA1, GBA2, RABGGTB | PSEN1 4565/4885PSEN2 3937/4885APH1B 2464/4885 |
| US-20240050410-A1 | TREATMENTS WITH NIROGACESTAT | GBA1, GBA2, RABGGTB | PSEN1 4565/4885PSEN2 3937/4885APH1B 2464/4885 |
| US-20240148695-A1 | TREATMENTS WITH NIROGACESTAT | GBA1, GBA2, RABGGTB | PSEN1 4565/4885PSEN2 3937/4885APH1B 2464/4885 |
| US-20240180874-A1 | IMPROVED TREATMENT OF OVARIAN CANCER WITH NIROGACESTAT | MUC1, GOLGA2, FOLH1 | PSEN1 4683/4885PSEN2 4508/4885APH1B 3615/4885 |
| US-20250025446-A1 | TREATMENTS WITH NIROGACESTAT | GBA1, GBA2, RABGGTB | PSEN1 4565/4885PSEN2 3937/4885APH1B 2464/4885 |
| US-11872211-B2 | Treatments with nirogacestat | GBA1, GBA2, RABGGTB | PSEN1 4565/4885PSEN2 3937/4885APH1B 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.